The table below shows ALNYLAM PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q3 2026
Q2 2026
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Revenue
$1.46B
$1.29B
-
$1.25B
$773.69M
-
Cost of revenue
$361.75M
$298.26M
-
$197.23M
$142.03M
-
Gross profit
-
-
-
-
-
-
R&D
$408.54M
$413.13M
-
$358.81M
$323.62M
-
ALNY annual revenue (10-K history)
ALNYLAM PHARMACEUTICALS, INC. reported annual revenue of $3.71B for fiscal year 2025. That is up 65.2% from $2.25B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $47.16M (FY 2016) to $3.71B. Figures come from the company's audited annual reports as filed with the SEC.
